Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$525.42K-$525.42KN/M vs Q1 2022 EPS Diluted$0.00$0.00no prior Q1 2022 on file Operating Income-$264,116N/M Operating Cash Flow-$251,017N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 22, 2023 · 52 d after period end